Geron Co. (GERN) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. grew its position in shares of Geron Co. (NASDAQ:GERN) by 1,211.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 248,803 shares of the biopharmaceutical company’s stock after purchasing an additional 229,827 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Geron were worth $249,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of GERN. BlackRock Inc. increased its position in shares of Geron by 7.9% during the 4th quarter. BlackRock Inc. now owns 15,038,176 shares of the biopharmaceutical company’s stock valued at $15,037,000 after purchasing an additional 1,102,419 shares during the period. Two Sigma Investments LP acquired a new position in shares of Geron during the 4th quarter valued at $985,000. Vanguard Group Inc increased its position in shares of Geron by 8.2% during the 3rd quarter. Vanguard Group Inc now owns 8,751,607 shares of the biopharmaceutical company’s stock valued at $15,403,000 after purchasing an additional 661,446 shares during the period. Vanguard Group Inc. increased its position in shares of Geron by 8.2% during the 3rd quarter. Vanguard Group Inc. now owns 8,751,607 shares of the biopharmaceutical company’s stock valued at $15,403,000 after purchasing an additional 661,446 shares during the period. Finally, Ibex Investors LLC acquired a new position in shares of Geron during the 4th quarter valued at $207,000. Institutional investors own 33.54% of the company’s stock.

GERN has been the topic of a number of recent research reports. ValuEngine upgraded Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. B. Riley upgraded Geron from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $1.50 to $3.25 in a report on Thursday, January 31st. BTIG Research initiated coverage on Geron in a report on Tuesday, February 12th. They issued a “buy” rating and a $4.00 target price on the stock. BidaskClub upgraded Geron from a “hold” rating to a “buy” rating in a report on Saturday, March 16th. Finally, Needham & Company LLC upgraded Geron from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Geron currently has an average rating of “Buy” and a consensus target price of $3.31.

Shares of NASDAQ GERN opened at $1.79 on Wednesday. Geron Co. has a 52-week low of $0.95 and a 52-week high of $6.99.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.05). The business had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.22 million. Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. Research analysts predict that Geron Co. will post -0.34 EPS for the current year.

In other news, EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total value of $241,270.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Geron Co. (GERN) Shares Bought by D. E. Shaw & Co. Inc.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.com-unik.info/2019/04/17/geron-co-gern-shares-bought-by-d-e-shaw-co-inc.html.

Geron Profile

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Article: What is a conference call?

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit